Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
Robert A. Burger, MD

Robert A. Burger, MD Physician

Director of Clinical Research and Fellowship Program in Gynecologic Oncology Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania

Dr. Burger is employed by Penn Medicine.

About Dr. Robert A. Burger

Recognized by America's Top Doctors, 2014 - 2018

Recognized by Best Doctors in America - 2013 - 2018

Recognized by Philadelphia magazine's annual Top Docs issues 2014 - 2018

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties

Specialty:

  • Gynecologic Oncology

Programs & Centers:

Board Certification:

  • Obstetrics and Gynecology - Gynecologic Oncology, 1999
  • Obstetrics and Gynecology, 1997

Clinical Expertise:

  • Cervical Cancer
  • Cervical Dysplasia
  • Cervical Lesions
  • Cervix Biopsy
  • Chemotherapy for Gynecologic Cancers
  • Colposcopy
  • Endometrial Cancer
  • Fallopian Tube Cancer
  • Gynecologic Cancer
  • Gynecologic Cancer Surgery
  • Gynecologic Surgery
  • Gynecology Clinical Trials
  • Hysterectomy (Uterus Surgery)
  • Hysteroscopy
  • Laparoscopic Hysterectomy
  • Laparoscopic Supracervical Hysterectomy
  • Laparoscopic Surgery
  • Laparoscopy
  • Loop Electrosurgical Excision Procedure (LEEP)
  • Minimally Invasive Hysterectomy
  • Ovarian Cancer
  • Robotic Surgery
  • Trophoblastic Cancer
  • Uterine Cancer
  • Vaginal Cancer
  • Vulvar Cancer

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: New York University School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: UC at Irvine Medical Center

Memberships

American Association for Cancer Research (AACR), National American College of Obstetricians and Gynecologists, National American College of Surgeons (FACS), fellow, National GOG Foundation, National Gynecologic Oncology Group, National National Cancer Institute (NCI), Investigator, National NRG Oncology, International NRG Oncology, National Ovarian Cancer National Alliance Scientific and Medical Advisory Board, National Society of Gynecologic Oncology (SGO), National

Hospital Affiliation

Dr. Burger is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ: Nomogram Predicting Individual Survival Following Recurrence in Advanced Stage High Grade Ovarian Cancer from NRG/GOG Randomized Trials of Platinum and Paclitaxel Obstetrics & Gynecology 133 (2): 245-54,2019.

Nasioudis D, Ko EM, Haggerty AF, Giuntoli II RL, Burger RA, Morgan MA, Latif NA: Role of adjuvant chemotherapy in the management of stage IC ovarian granulosa cell tumors Gynecologic Oncology Reports In Press : 2019.

Moore KN, Gunderson C, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger R, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE: A Phase 1b Dose Escalation Study of Ipafricept (OMP-54F28) in Combination with Paclitaxel and Carboplatin in Patients with Recurrent Platinum-Sensitive Ovarian Cancer Gynecol Oncol In Press : 2019.

Nasioudis D, Ko E, Haggerty AF, Giuntoli RL II, Burger RA, Morgan RA, Latif N: Isolated distant lymph node metastases in ovarian cancer. Should a new sub-stage be created? Gynecologic Oncology Reports In Press : 2019.

Arend RC, Toboni M, Montgomery AM, Burger RA, Olawaiye AB, Monk BJ, Herzog T.: Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm. The Oncologist 12 : 1533-1545,2018.

Fu S; Corr B; Hamilton E; Burger RA; Wenham R; Naumann RW; Stagg R; Moore KN: A Phase 1b Study of Navicixizumab & Weekly Paclitaxel in Heavily Pre-Treated Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer. Presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany. (Abstract) : 2018.

Burger RA, Deng W, Makker V, Collins Y, Gray H Debernardo R, Martin LP, Aghajanian C.: Phase II Evaluation of Dalantercept in the Treatment of Persistent or Recurrent Epithelial Ovarian Cancer: an NRG Oncology/Gynecologic Oncology Group Study Gynecol Oncol 150 (3): 466-470,2018.

Nasioudis D; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Ko EM; Latif NA.: Type of treatment facility impacts survival of patients with ovarian clear cell carcinoma. Poster presentation at the Biennial Meeting of the International Society of Gynecologic Cancer, Kyoto, Japan. (Abstract) : 2018.

Nasioudis D; Kanninen T; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Ko EM; Latif NA.: Residual disease is associated with a worse prognosis in patients with advanced stage sex cord-stromal tumors. Poster presentation at the Biennial Meeting of the International Society of Gynecologic Cancer, Kyoto, Japan. (Abstract) : 2018.

Burger RA; Sill M; Zamarin D; Powell D; Frak I; Zivanovic O; Gunderson C; Ko E; Mathews C; Sharma S; Hagemann A; Khleif S; Aghajanian C: NRG Oncology Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Ovarian Cancer. Late breaking abstract oral presentation at the Biennial Meeting of the International Society of Gynecologic Cancer, Kyoto, Japan. (Abstract) : 2018.

Academic Contact Info

University of Pennsylvania
3400 Civic Center Blvd.
South Tower 10-173

Philadelphia, PA 19104-5156
Phone: (215) 220-9513
Patient appointments: 800-789-7366 (PENN)